Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig M Kessler

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Research and Practice in Thrombosis and Haemostasis|September 29, 2022
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3Michael U Callaghan, Elina Asikanius, Michaela Lehle, et al.
Journal of Thrombosis and Haemostasis : JTH|April 30, 2019
Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort studyClive Kearon, Sameer Parpia, Frederick A Spencer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 27, 2025
Operationalising a Haemophilia Gene Editing Lexicon for Practical UseWilliam McKeown, Cedric Hermans, Carmen Unzu, et al.
European Journal of Haematology|March 21, 2017
Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) studyTyler W Buckner, Michelle Witkop, Christine Guelcher, et al.
Journal of Vascular Surgery|January 18, 2008
Acute venous disease: venous thrombosis and venous traumaMark H Meissner, Thomas W Wakefield, Enrico Ascher, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 27, 2022
First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia BPaul Harmatz, Carlos E Prada, Barbara K Burton, et al.
Journal of Thrombosis and Haemostasis : JTH|October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 yearsNeil A Goldenberg, Sam Schulman, John M Kittelson, et al.
Plos One|May 14, 2013
Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonanceKenneth B Lewis, Richard J Hughes, Melinda S Epstein, et al.
Annals of Internal Medicine|January 7, 2015
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort studyClive Kearon, Frederick A Spencer, Denis O'Keeffe, et al.
JAMA|January 11, 2022
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical TrialNeil A Goldenberg, John M Kittelson, Thomas C Abshire, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Research and Practice in Thrombosis and Haemostasis|September 29, 2022
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3Michael U Callaghan, Elina Asikanius, Michaela Lehle, et al.
Journal of Thrombosis and Haemostasis : JTH|April 30, 2019
Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort studyClive Kearon, Sameer Parpia, Frederick A Spencer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 27, 2025
Operationalising a Haemophilia Gene Editing Lexicon for Practical UseWilliam McKeown, Cedric Hermans, Carmen Unzu, et al.
European Journal of Haematology|March 21, 2017
Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) studyTyler W Buckner, Michelle Witkop, Christine Guelcher, et al.
Journal of Vascular Surgery|January 18, 2008
Acute venous disease: venous thrombosis and venous traumaMark H Meissner, Thomas W Wakefield, Enrico Ascher, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 27, 2022
First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia BPaul Harmatz, Carlos E Prada, Barbara K Burton, et al.
Journal of Thrombosis and Haemostasis : JTH|October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 yearsNeil A Goldenberg, Sam Schulman, John M Kittelson, et al.
Plos One|May 14, 2013
Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonanceKenneth B Lewis, Richard J Hughes, Melinda S Epstein, et al.
Annals of Internal Medicine|January 7, 2015
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort studyClive Kearon, Frederick A Spencer, Denis O'Keeffe, et al.
JAMA|January 11, 2022
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical TrialNeil A Goldenberg, John M Kittelson, Thomas C Abshire, et al.
Pageof 9